SG11201408619WA - Saxagliptin salts - Google Patents

Saxagliptin salts

Info

Publication number
SG11201408619WA
SG11201408619WA SG11201408619WA SG11201408619WA SG11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA
Authority
SG
Singapore
Prior art keywords
saxagliptin
international
delhi
singh
del
Prior art date
Application number
SG11201408619WA
Other languages
English (en)
Inventor
Ram Chander Aryan
Ashwani Kumar Singh
Amit Sharma
Ramendra Singh Rathore
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of SG11201408619WA publication Critical patent/SG11201408619WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201408619WA 2012-07-02 2013-07-02 Saxagliptin salts SG11201408619WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2061DE2012 2012-07-02
IN3917DE2012 2012-12-19
PCT/IB2013/055429 WO2014006569A2 (fr) 2012-07-02 2013-07-02 Sels de saxagliptine

Publications (1)

Publication Number Publication Date
SG11201408619WA true SG11201408619WA (en) 2015-01-29

Family

ID=54193750

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408619WA SG11201408619WA (en) 2012-07-02 2013-07-02 Saxagliptin salts

Country Status (5)

Country Link
EP (1) EP2867206A2 (fr)
AU (1) AU2013285078A1 (fr)
CA (1) CA2879824A1 (fr)
SG (1) SG11201408619WA (fr)
WO (1) WO2014006569A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2861560B1 (fr) 2012-05-24 2018-08-08 Apotex Inc. Sels de saxagliptine avec des acides organiques
WO2015166466A1 (fr) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Forme cristalline d'acétate de saxagliptine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
TW200538122A (en) 2004-03-31 2005-12-01 Bristol Myers Squibb Co Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7741082B2 (en) 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
US7214702B2 (en) 2004-05-25 2007-05-08 Bristol-Myers Squibb Company Process for producing a dipeptidyl peptidase IV inhibitor
PE20090696A1 (es) * 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
EP2417107B1 (fr) 2009-04-09 2015-08-26 Sandoz AG Formes cristallines de la saxagliptine
WO2012017028A1 (fr) 2010-08-06 2012-02-09 Sandoz Ag Nouveau composé cristallin comprenant de la saxagliptine et de l'acide phosphorique
WO2012017029A1 (fr) * 2010-08-06 2012-02-09 Sandoz Ag Nouveaux sels de saxagliptine comportant des diacides organiques
EP2608788A1 (fr) 2010-10-04 2013-07-03 Assia Chemical Industries Ltd. Polymorphes de chlorhydrate de saxagliptine et leurs procédés de préparation
CN102086172A (zh) * 2011-01-13 2011-06-08 廖国超 沙格列汀的药用盐及其制备方法

Also Published As

Publication number Publication date
EP2867206A2 (fr) 2015-05-06
CA2879824A1 (fr) 2014-01-09
AU2013285078A1 (en) 2015-01-29
WO2014006569A2 (fr) 2014-01-09
WO2014006569A3 (fr) 2014-03-06

Similar Documents

Publication Publication Date Title
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201808990QA (en) Compositions for topical application of compounds
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201809559UA (en) Substituted pyridines as inhibitors of dnmt1
SG11201408261UA (en) Syringe
SG11201407220YA (en) N-alkyltriazole compounds as lpar antagonists
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201408739VA (en) Inhibitors of hepatitis c virus
SG11201407458XA (en) TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201408094YA (en) Neprilysin inhibitors
SG11201804811WA (en) Fenfluramine compositions and methods of preparing the same
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201407988UA (en) Process for improved opioid synthesis
SG11201407934UA (en) Camsylate salt
SG11201900545TA (en) Pharmaceutical compounds
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201407337QA (en) Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same